“We originally raised about six million from what we call friends and family, and then we also raised two and a ... it was ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

data-text="Merck Announces Emerging Biotech Grant Program Winners" data-link=" Announces Emerging Biotech Grant Program ...

Kepler Capital analyst David Evans maintained a Buy rating on Merck KGaA (0O14 – Research Report) on November 1 and set a price target ...

With its portfolio of cancer medicines and one of the pharma industry's most recognizable names, it's no surprise that investors are curious about whether to buy shares of Merck (NYSE: MRK).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on ...

Merck and Intel have launched a collaborative academic research initiative in Europe, bringing together eleven institutions ...

Award recipients to receive in-kind technologies and services to accelerate therapeutics to market <li /> Merck e ...